Pine Labs, Exotel, Emami, Kohli's One8 & Sun Pharma's $11.75B Mega Deal | Decoding Exits

ELI5 / TLDR

Blume’s monthly M&A walk-through, April edition. Six deals across four flavours: a fintech tuck-in (Pine Labs bought Shopflo for Rs 88 cr cash), a healthcare hand-off (Redcliffe sold Krista IVF to MMG’s Moon Care for ~Rs 100 cr), an Indian voice-AI buy (Exotel acquired Dubverse), two consumer brand exits (Emami taking control of Axiom Ayurveda for ~Rs 200 cr, Virat Kohli’s One8 leaving Puma for Agilitas Sports), and the headline gorilla — Sun Pharma’s $11.75 billion takeover of US-listed Organon. The thread running through it: Indian tech companies finally have IPO cash and listed stock as deal currency, which is starting to unlock the long-promised M&A flywheel.

The Full Story

Why M&A is finally moving

Karthik (presenting Daga’s research) opens with the structural point. Indian tech M&A was historically thin because nobody had the currency. Private companies hoarded cash for growth; sellers didn’t want unlisted stock; EBITDA was scarce. With 30-40 listed tech companies now sitting on IPO cash and trading liquid scrip, both sides of the table suddenly have options. Inorganic growth stops looking exotic.

Pine Labs / Shopflo — Rs 88 cr cash

Pine Labs, freshly public after last year’s multi-billion-dollar IPO, paid Rs 88 cr in cash for Shopflo, a Gurgaon-based D2C checkout-optimisation SaaS, 4-5 years old, backed by Tiger, Better Capital and TQ Ventures. On rumoured FY25 revenue of Rs 15.5 cr that’s roughly a 6x multiple. Pine Labs is heavy in offline POS; Shopflo plugs them into the online D2C checkout layer. Karthik frames it as the Indian version of Stripe buying checkout.com, or PayU buying ZestMoney — the larger fintech acquires an adjacent value-chain layer rather than building it.

Krista IVF — strategic-to-strategic

Redcliffe Labs, a diagnostics company, had built Krista IVF since 2018 into a 50-plus-centre chain doing ~Rs 100 cr revenue and turning profitable. They sold it to Moon Care Private, the healthcare arm of the MMG group, for roughly Rs 100 cr. The interesting bit isn’t the price, it’s the shape: a strategic that incubated a non-core asset selling to a strategic that wants it as a frontline business. Karthik notes the largest IVF chain in India is still only around 150 centres — plenty of room for roll-ups, and he wouldn’t be surprised to see a billion-dollar IVF aggregator emerge by decade-end.

Exotel / Dubverse — voice AI into the CX stack

A Blume portfolio deal. Exotel, the 15-year-old cloud-comms platform processing 20-billion-plus interactions a year, bought Dubverse — an AI speech and dubbing suite covering 70+ languages with deep Indian-language coverage and ~3 million users. Dubverse runs as an independent product, but Exotel gets the team, the engineers, and an AI moat without building it from scratch. CEO Shivku’s public framing: AI can handle 60% of customer support. The thesis Karthik underlines is that customer experience is moving to voice AI, and the CX space will see relentless consolidation for the rest of the decade.

Emami / Axiom Ayurveda — Rs 200 cr, founders fully out

Axiom owns Alo Frooti (aloe-vera-pulp beverages) plus Jeevan Ras and Mukti Gold — a profitable health-and-wellness drinks portfolio doing ~Rs 180 cr expected FY26 revenue with offline distribution. Emami had taken 26.5% in September ‘23. They’re now adding another 36%-plus to reach 63%, with a final tranche later this year. Total deal ~Rs 200 cr. Founders and existing shareholders fully exit. Karthik slots it into a wider pattern — ITC buying Yoga Bar and Sprout Life, Dabur buying Badshah Masala — where legacy FMCG houses are extending into health-and-wellness or modern food brands. He flags the brutal asymmetry of brand valuations: a Rs 180 cr brand sells for Rs 200 cr while a Rs 350 cr brand can sell for Rs 3,000 cr. Growth rate and margin structure are everything; revenue alone is a weak anchor.

One8 — from Puma to Agilitas

Virat Kohli’s One8 (his jersey number) was lived under Puma India as a licensee — internet-first premium athleisure. It’s moved to Agilitas Sports, founded in 2023 by Abhishek Ganguly, the ex-MD of Puma India and Southeast Asia who actually oversaw the original Puma-One8 deal. Same operator, new vehicle. Agilitas is building a vertically integrated manufacturing-to-retail platform and has already picked up Mochi shoes. Kohli’s recycled his payout back in as a minority shareholder. Karthik draws the line to Jordan/Nike, LeBron and Federer/On — sports brands as equity stakes, not just licensing fees. The flywheel’s just starting to spin in India.

Sun Pharma / Organon — the $11.75 billion gorilla

The headline. Sun Pharma, already India’s number-one pharma company at $6.2 billion in revenue, is buying New Jersey-based Organon — a women’s health and biosimilars business with 70-plus products across 140 markets, spun off from Merck five years ago. Total enterprise value $11.75 billion: ~$3.15 billion equity, ~$8.6 billion net debt. Funding: ~$10 billion bank financing plus $2 billion internal cash. Pro-forma combined revenue lands near $12 billion, which puts the combined entity inside the global top 25. Subject to global antitrust, FDI, shareholder approvals — but if it closes, Dilip Shanghvi’s small-town generics company has just made a serious play for global scale.

Key Takeaways

The Indian M&A flywheel has finally turned. Listed tech companies with IPO cash and liquid stock are now credible acquirers; sellers will take the paper.
Fintech consolidates by adjacency. Pine Labs/Shopflo is the template — offline incumbents buying online layers rather than building them.
FMCG keeps eating health-and-wellness D2C. Emami/Axiom joins ITC/Yoga Bar, Dabur/Badshah. Sub-Rs 300 cr brands are now a routine acquisition class.
Brand valuations are non-linear. Rs 180 cr revenue → Rs 200 cr exit. Rs 350 cr revenue → Rs 3,000 cr exit. Growth and margin compound the multiple in violent ways.
Voice AI is the next CX consolidation theme. Exotel/Dubverse is one node in what Karthik expects to be a decade-long roll-up.
Athlete brands are graduating from licensing to equity. One8 to Agilitas mirrors Jordan/Nike, Federer/On.
Sun/Organon is the largest Indian pharma outbound deal in memory — $10B of bank financing on a single transaction is a statement about how Indian balance sheets are being deployed globally.

Claude’s Take

Decoding Exits is one of the more useful monthly reads in Indian VC media — Karthik talks like someone who actually sat in the rooms, not a content team rephrasing TechCrunch. The Pine Labs and Exotel commentary lands because he’s been close to both founders for years; the framing of “now there’s currency for M&A” is the right way to read this cycle, and it’s not how the mainstream business press tends to package these deals.

The weaker stretch is the brand valuation aside — “180 cr brand for 200, 350 cr brand for 3,000” is true but he doesn’t explain why (international scalability premium, gross margin, growth velocity), which is the actually interesting bit. The Sun/Organon section is also more recitation than insight; the genuinely interesting question is whether bolting a US women’s-health and biosimilars business onto an Indian generics champion creates revenue synergy or just leverage, and he doesn’t go there.

Score 7. Solid monthly digest with structural commentary you won’t get from headline coverage. Drops a point for skating past the most analytically interesting questions in the bigger deals.

Pine Labs, Exotel, Emami, Kohli's One8 & Sun Pharma's $11.75B Mega Deal | Decoding Exits | April